Panobinostat plus bortezomib and dexamethasone in previously treated multiple myeloma: outcomes by prior treatment - Test2 - elhamkhani - TriplyDB

Panobinostat plus bortezomib and dexamethasone in previously treated multiple myeloma: outcomes by prior treatment

Panobinostat plus bortezomib and dexamethasone in previously treated multiple myeloma: outcomes by prior treatment

http://www.wikidata.org/entity/Q33428098

about

Novel agents in the treatment of multiple myeloma: a review about the future Clinical use and applications of histone deacetylase inhibitors in multiple myeloma The Role of Panobinostat Plus Bortezomib and Dexamethasone in Treating Relapsed or Relapsed and Refractory Multiple Myeloma: A European Perspective Triplet combinations in relapsed/refractory myeloma: update on recent phase 3 trials.The next generation of novel therapies for the management of relapsed multiple myeloma.Efficacy and Safety of Panobinostat in Relapsed or/and Refractory Multiple Myeloma: Meta Analyses of Clinical Trials and Systematic Review.Deacetylase inhibitors: an advance in myeloma therapy?Phase I/II study of docetaxel combined with resminostat, an oral hydroxamic acid HDAC inhibitor, for advanced non-small cell lung cancer in patients previously treated with platinum-based chemotherapy.Panobinostat plus bortezomib and dexamethasone: impact of dose intensity and administration frequency on safety in the PANORAMA 1 trial.Efficacy and tolerability of the histone deacetylase inhibitor panobinostat in clinical practice.Why cure, why now?Histone deacetylase inhibitors inhibit metastasis by restoring a tumor suppressive microRNA-150 in advanced cutaneous T-cell lymphoma.Histone deacetylase inhibitors provoke a tumor supportive phenotype in pancreatic cancer associated fibroblasts.Current and developing synthetic pharmacotherapy for treating relapsed/refractory multiple myeloma.A gene expression signature distinguishes innate response and resistance to proteasome inhibitors in multiple myeloma.Panobinostat: A Review in Relapsed or Refractory Multiple Myeloma.Modern multiple myeloma therapy: deep, sustained treatment response and good clinical outcomes.Panobinostat for the treatment of acute myelogenous leukemia.Safety issues and management of toxicities associated with new treatments for multiple myeloma.Developments in the Field of Myeloma in the Last Decade.Therapy for Relapsed Multiple Myeloma: Guidelines From the Mayo Stratification for Myeloma and Risk-Adapted Therapy.Novel Proteasome Inhibitors and Histone Deacetylase Inhibitors: Progress in Myeloma Therapeutics.Epigenetic regulatory mutations and epigenetic therapy for multiple myeloma.Emerging drugs and combinations to treat multiple myeloma.The proteasome and proteasome inhibitors in multiple myeloma.A phase 1 trial of the HDAC inhibitor AR-42 in patients with multiple myeloma and T- and B-cell lymphomas.NCCN Guidelines Insights: Multiple Myeloma, Version 3.2016.Triplet vs. doublet drug regimens for managing multiple myeloma.Cancer epigenetics: Moving forward.

P2860

Q26745924-105F6E2F-1346-4465-A098-402D77384AB0 Q26745930-B0E0D3E8-FCFD-4378-B92D-5FB96BA4E9C3 Q28069789-0E603ACF-4FC3-4D10-B204-75B3AED24375 Q30238893-C9717079-2938-4B92-9C74-D353044E8A3C Q30248534-0842C828-FF08-4C78-A278-1846351F6F87 Q33432845-722CD080-6C5C-4A80-853D-5980102CDC54 Q33438321-C502D497-C224-4DA1-8AAB-AE33E06880A5 Q33438820-87EA4671-C214-4C92-A79F-F622195FE77B Q33443001-CFB89B25-7880-48E2-87DE-902EAA305F5E Q33443417-F0ECB423-1FE6-423E-A762-AF434C323224 Q37627236-347278E6-EE10-432B-B37C-94B1E475E23A Q37702571-E26FB53C-F5AB-40BD-B144-61C23EED554F Q37745937-A8657581-2FE6-48EB-980C-696C908F3CFB Q38672091-3F484433-9D8A-461F-B310-5FBF18B1B958 Q38700339-3FB1189E-C8E6-4A73-B215-379252DD60E8 Q38716460-E6F55110-85A0-421D-A341-F1391FE4D440 Q38756800-219F3BD8-09E9-4A29-8767-BE4E78A8BCCF Q38835113-4E780A7B-7D19-46FB-BB44-97AA51BDCB80 Q39100317-E032DABC-C078-49F8-B993-92AB95C2E8A3 Q39134193-88AC73C4-C4A3-41BF-AF00-6E8025D9C32C Q39177792-244B1BF9-E3DB-4D2F-90F4-9865CA29FF41 Q39234159-E2FB2E68-6495-4E49-8168-3D5E28E33FFB Q39261435-3C287D12-A1A4-47BE-9BBA-3F8FF8D81561 Q41694198-CB2D1B93-58E7-41F9-ADAE-49A26D001874 Q47339695-B25EE877-9806-4089-9102-961041FB2485 Q47584543-1D22DDA3-E26A-4856-B840-8D00CBE5A65C Q47625488-F572816F-3F50-4087-97B6-B81F7DB2F7D3 Q47770089-45B4C897-445F-4955-8256-78A95E11ADDB Q55177661-F82B4916-8040-48CF-B483-BB5D944B731D

P2860

Panobinostat plus bortezomib and dexamethasone in previously treated multiple myeloma: outcomes by prior treatment

http://www.wikidata.org/entity/Q33428098

description

2015 nî lūn-bûn

@nan

2015 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年学术文章

@wuu

2015年学术文章

@zh-cn

2015年学术文章

@zh-hans

2015年学术文章

@zh-my

2015年学术文章

@zh-sg

2015年學術文章

@yue

name

Panobinostat plus bortezomib a ...... a: outcomes by prior treatment

@ast

Panobinostat plus bortezomib a ...... a: outcomes by prior treatment

@en

type

label

Panobinostat plus bortezomib a ...... a: outcomes by prior treatment

@ast

Panobinostat plus bortezomib a ...... a: outcomes by prior treatment

@en

prefLabel

Panobinostat plus bortezomib a ...... a: outcomes by prior treatment

@ast

Panobinostat plus bortezomib a ...... a: outcomes by prior treatment

@en

P1433

Q33428098-FF751446-F800-4EE0-8885-E603D178C285

P1476

Q33428098-3CF9575E-795D-4972-A5D3-0B204147D7B9

P2093

Q33428098-0026E512-F227-4DE3-AF2A-E415C3C0B464

Q33428098-07EE48C4-D346-4C75-B45B-A3305452EE89

Q33428098-0FDA7825-D629-4FD9-9AC1-53AACE0B5740

Q33428098-25EF200D-30A5-4658-A8B1-876B7B3AE712

Q33428098-316E3E3C-99A7-4FF2-B74F-979EEB34C1F3

Q33428098-3B25FB4A-EE19-4C52-8B69-90AC8E50A689

Q33428098-44338A8E-E1CC-4E73-AC0F-18C18AC5D370

Q33428098-4C482CA1-DB6F-4150-A6E4-745C289FF47E

Q33428098-5353470A-6DCA-49D9-B148-96ECFC869B12

Q33428098-58133274-8738-408E-A6FF-BF4703D3CDC2

P2860

Q33428098-057B1A6F-8B72-403D-BFB9-D2B8A198A8A3

Q33428098-1A529930-C89F-4F6B-9C4F-15A6A613BFB0

Q33428098-1E3BA389-9643-4875-B3FD-1CF6AF7A72C1

Q33428098-2992EAE7-02A7-4FA3-A120-015C780218DA

Q33428098-391BCE55-EDEE-4254-91F1-B07FE8609C43

Q33428098-432C89CB-6770-4593-8E04-2BC9F9F94B94

Q33428098-458B598F-BC49-4EC8-B557-7EC7E5A42E49

Q33428098-46EDF968-5C36-43C8-AF7A-BEE310A7375E

Q33428098-4FAB41FE-84BC-49F6-8760-28266372B544

Q33428098-5E5CAD62-B7B8-4D0C-A341-E2FF1B054A08

P304

Q33428098-B8F6FD8D-E1A4-49C4-8CC2-4D4DD049EAFD

P31

Q33428098-C496C6C0-D02C-444B-A9F4-EF83B9AA0726

P356

Q33428098-7571D2E2-B1FA-4B6E-AC98-FD87ACE9AE35

P407

Q33428098-38DB350B-4B8B-4733-9916-CC015C5C36BF

P433

Q33428098-7E8E4947-462B-4FA8-8EE1-8A26256FAD2F

P478

Q33428098-825109F2-298C-4BD4-900D-80793E985D8C

P50

Q33428098-2AD7321B-9239-4071-AF31-812C71022FC1

Q33428098-3420A137-E481-44BE-84C7-02C832484C7A

Q33428098-773FEE85-6D61-41FF-9121-ACAE358E7BAE

Q33428098-8EA5F1EE-C8E7-4197-9D24-4BCD3D9209D1

Q33428098-B140702F-4D6C-4F57-AAC4-E7B4FEA5C6DB

Q33428098-D029516B-F20D-409A-87AB-6D2685E8C22C

Q33428098-DC7B38E1-5419-43D7-8E7E-AB8473694C94

P577

Q33428098-D15DC469-0580-4F59-A3B1-EC907EC74885

P698

Q33428098-6C6E9C79-8BE5-4C96-B635-8DF64411396F

P921

Q33428098-4A152858-0119-4A80-9872-F351E89FDB37

P932

Q33428098-5909A09E-366A-4E5B-BDA3-87E01FCC1D67

P356

BLOOD-2015-09-665018

P1433

P1476

Panobinostat plus bortezomib a ...... a: outcomes by prior treatment

@en

P2093

Andreas Guenther

http://www.w3.org/2001/XMLSchema#string

Bourras-Rezki Bengoudifa

http://www.w3.org/2001/XMLSchema#string

Claudia Corrado

http://www.w3.org/2001/XMLSchema#string

Florence Binlich

http://www.w3.org/2001/XMLSchema#string

Jae Hoon Lee

http://www.w3.org/2001/XMLSchema#string

Jesús F San-Miguel

http://www.w3.org/2001/XMLSchema#string

Jian Hou

http://www.w3.org/2001/XMLSchema#string

Meral Beksac

http://www.w3.org/2001/XMLSchema#string

Noppadol Siritanaratkul

http://www.w3.org/2001/XMLSchema#string

Robert L Schlossman

http://www.w3.org/2001/XMLSchema#string

P2860

A phase 2 study of bortezomib in relapsed, refractory myeloma.

Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma.

A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma.

PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma.

Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial.

Phase Ib study of panobinostat and bortezomib in relapsed or relapsed and refractory multiple myeloma.

Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial.

Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study.

Better quality of response to lenalidomide plus dexamethasone is associated with improved clinical outcomes in patients with relapsed or refractory multiple myeloma.

Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant.

P304

713-721

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2015-09-665018

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

127

http://www.w3.org/2001/XMLSchema#string

P50

Hermann Einsele

Meletios A. Dimopoulos

Ashraf Elghandour

Paul G Richardson

Philippe Moreau

P577

2015-12-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26631116

http://www.w3.org/2001/XMLSchema#string

P921

P932

4760132

http://www.w3.org/2001/XMLSchema#string